PDC*line Pharma logo

PDC*line Pharma

A biotechnology company developing a first in class Plasmacytoid Dendritic cell line, PDC*line providing unmatched advantages Immunooncology neoantigen PDC*line Pharma is the clinical-stage biotech developing potent and scalable therapeutic cancer vaccines based on a cell line of Plasmacytoid Dendritic Cells (PDC*line).

PDC*line Pharma is Spin-off of the EFS (French blood service) and has access to EFS (French blood service) R&D and GMP facilities.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.pdc-line-pharma.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
c/o EFS, 29 avenue des Maquis du Gresivaudan, 38701
La Tronche
France
Email
Contact Number
+33 634 367747

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/pdc-line-pharma” connections=”true” suffix=””]

PDC*vac is a therapeutic cancer vaccine platform based on a unique cell line of Plasmacytoid Dendritic Cells (PDC*line). PDC*line is fully qualified, safe, easy to expand and manipulate. It is loaded with peptides derived from a combination of tumor antigens to avoid immune escape.

In Dec 2016, PDC*line Pharma raises ‹4 Mn in a first round, including ‹2.6Mn in capital and ‹1.4Mn in bank loans, grants and recoverable advances.